Expanding HIV Prevention Options in the Asia-Pacific Region

Cabotegravir is an antiretroviral that can be used as a long-acting injectable formulation (CAB LA) for both treatment and prevention of HIV in adults and adolescents. Although the drug is approved for use in multiple countries, access remains severely limited in the Asia-Pacific region due to a lack of uptake by national programs, limited regulatory approvals, and the absence of generic low-cost formulations.

amfAR’s TREAT Asia program has prepared a summary on the basics of CAB LA as a pre-exposure prophylaxis (PrEP) option.

Read the Snapshot here.